scholarly journals Anti–Vascular Endothelial Growth Factor Resistance in Exudative Macular Degeneration and Polypoidal Choroidal Vasculopathy

2019 ◽  
Vol 3 (9) ◽  
pp. 744-752 ◽  
Author(s):  
Gregg T. Kokame ◽  
Talisa E. deCarlo ◽  
Kyle N. Kaneko ◽  
Jase N. Omizo ◽  
Rebecca Lian
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Macular Degeneration ◽  
Polypoidal Choroidal Vasculopathy ◽  
Vascular Endothelial ◽  
Exudative Macular Degeneration ◽  
Endothelial Growth Factor ◽  
Choroidal Vasculopathy

scholarly journals The Use of Vascular Endothelial Growth Factor Inhibitors and Complementary Treatment Options in Polypoidal Choroidal Vasculopathy: A Subtype of Neovascular Age-Related Macular Degeneration

2018 ◽  
Vol 19 (9) ◽  
pp. 2611 ◽  
Author(s):  
Kelvin Teo ◽  
Mark Gillies ◽  
Samantha Fraser-Bell
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Macular Degeneration ◽  
Polypoidal Choroidal Vasculopathy ◽  
Age Related Macular Degeneration ◽  
Vascular Endothelial ◽  
Vegf Inhibitors ◽  
Age Related ◽  
Endothelial Growth Factor ◽  
Choroidal Vasculopathy

Polypoidal choroidal vasculopathy (PCV) is a subtype of neovascular age-related macular degeneration (AMD; nAMD) which occurs more commonly in Asian populations as compared to Caucasians. PCV and nAMD share pathological mechanisms, including pathological expression of vascular endothelial growth factor (VEGF). The advent of anti-vascular endothelial growth factor (VEGF) revolutionized the treatment of nAMD. Despite being a subtype of nAMD, PCV responds less well to VEGF inhibitors; thus, photodynamic therapy (PDT) in combination with anti-VEGF treatment may be considered. This review aims to summarize the current evidence for the treatment of PCV, especially whether VEGF inhibitors should be used alone or in combination with PDT.

Sign in / Sign up

Export Citation Format

Share Document